AZN (AZN) Stock Price & Analysis
AZN (AZN) rose 1.04% to USD 183.43 as of June 9, 2026 at 23:45 UTC, according to Nexqual real-time market data.
AZN last closed at USD 181.55; the session ranged USD 181.16–183.81 on volume of 1,801,213 shares. Market capitalization is $284.47B, with a 52-week range of USD 137.22–212.71 (NYQ). Source: Nexqual, June 9, 2026 at 23:45 UTC.
Key Statistics (as of June 9, 2026 at 23:45 UTC)
| Price | USD 183.43 |
|---|---|
| Change | ▲ 1.04% (up) |
| Previous Close | USD 181.55 |
| Open | USD 181.73 |
| Day Range | USD 181.16 – 183.81 |
| 52-Week Range | USD 137.22 – 212.71 |
| Volume | 1,801,213 shares |
| Market Cap | $284.47B |
| Exchange | NYQ |
Technical Analysis (AZN)
Nexqual's technical model rates AZN "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:45 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.02 (neutral) |
| vs SMA50 | Below (USD 190.17) |
| MACD | -1.83 (negative) |
Analyst Ratings (AZN)
Wall Street analysts rate AZN "Strong Buy" based on 10 analysts, with a mean price target of USD 224.49 (range USD 184–245), per Nexqual as of June 9, 2026 at 23:45 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 224.49 |
| High Target | USD 245 |
| Low Target | USD 184 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (AZN)
| Next Earnings Date | 2026-07-27 |
|---|---|
| EPS Estimate | USD 1.27 |
| Revenue Estimate | $15.39B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.29 vs est 1.27 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Financials & Fundamentals (AZN)
| Total Revenue | $60.44B |
|---|---|
| Revenue Growth (YoY) | +12.50% |
| Gross Margin | +81.50% |
| Operating Margin | +27.94% |
| Profit Margin | +17.19% |
| ROE | +23.48% |
| Debt / Equity | 71.82 |
| Current Ratio | 0.91 |
| Total Cash | $7.67B |
| Total Debt | $34.03B |
| Free Cash Flow | $6.56B |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Financial Health Score (AZN)
Nexqual rates AZN's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:45 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 82%, operating 28% |
| Balance Sheet | Mixed — $7.67B cash vs $34.0B debt |
| Cash Flow | Solid — FCF $6.56B, 11% margin |
| Efficiency | Strong — ROE 23%, ROA 8.5% |
Ownership (AZN)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +65.04% |
| Shares Outstanding | 1.55B |
| Float | 1.54B |
| Short % of Float | +0.14% |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Leadership (AZN)
AZN is led by Pascal Claude Roland Soriot D.V.M. (age 66), CEO & Executive Director, per Nexqual as of June 9, 2026 at 23:45 UTC.
| CEO & Executive Director | Pascal Claude Roland Soriot D.V.M. (age 66) |
|---|---|
| CFO & Executive Director | Aradhana Sarin (age 51) |
| Executive Vice-President of BioPharmaceuticals Business Unit | Ruud Dobber |
| Executive Vice President of Oncology R & D | Susan Mary Galbraith (age 59) |
| Executive Vice President of International | Iskra Reic |
Major Backers & Investors (AZN)
Notable institutional backers of AZN include Investor AB, Capital International Investors, FMR, LLC, according to Nexqual as of June 9, 2026 at 23:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Investor AB | 3.33% |
| Capital International Investors | 2.22% |
| FMR, LLC | 1.91% |
| Capital Group | 1.82% |
| Wellington Management | 1.53% |
| Price (T.Rowe) Associates Inc | 1.26% |
| Bank of America Corporation | 1.23% |
| JPMorgan | 1.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.75% |
| Legal & General Group PLC | 1.67% |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GSK | GSK plc | USD 51.25 | ▼ 0.52% |
| NVS | Novartis AG | USD 149.12 | ▼ 0.03% |
| SNY | Sanofi | USD 44.73 | ▼ 0.64% |
| MRNA | Moderna, Inc. | USD 47.73 | ▲ 0.61% |
| BNTX | BioNTech SE | USD 86.5 | ▼ 1.79% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:45 UTC. This page is informational and not investment advice.